At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 49 enrolled
Drug / intervention
N91115 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating N91115, Placebo, and 1 other intervention for Healthy. Completed, enrolled 49 participants across 1 site.
Detailed Summary
A study in healthy subjects to assess the safety, tolerability, and pharmacokinetics of N91115.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartFeb 2014
Primary CompletionDec 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedDec 17, 2013
Enrollment StartFeb 1, 2014
Primary CompletionDec 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 12.5 years ago
Interventions
N91115drug
Given PO daily for 14 days
Placebodrug
Given PO daily for 14 days
N91115drug
Given PO only on Day 1
Placebo-Day 1 onlydrug
Given PO- only on Day 1 (single dosed to match single dose treatments)